Patients’ symptoms were evaluated on the Positive and Negative Syndrome Scale (PANSS), a clinician-rated tool used to assess schizophrenia symptoms.2
Positive symptoms
- Delusions
- Hallucinations
- Disorganized thoughts
Negative symptoms
- Social withdrawal
- Emotional withdrawal
- Reduced speech
General psychopathology
- Anxiety
- Depression
- Attention
WELTRUZA reduced total PANSS scores across all 3 doses by week 8.1*
*In an 8-week, randomized, double-blind, placebo-controlled study, WELTRUZA met the primary endpoint of change from baseline in PANSS total score at week 8 versus placebo. The least squares (LS) mean changes from baseline to week 8 with WELTRUZA were -21.91, -23.44, and -21.93 for 318 mg, 425 mg, and 531 mg, respectively, versus -12.17 for placebo.3
The power to help improve acute symptoms and sustain improvements across all doses1,3
22.4-point reduction in PANSS total score with WELTRUZA vs 12.17 with placebo (P<.0001)3
In an 8-week, randomized, double-blind, placebo-controlled study, WELTRUZA met the primary endpoint of change from baseline in PANSS total score at week 8 versus placebo1
The least squares (LS) mean changes from baseline to week 8 with WELTRUZA were -21.91, -23.44, and -21.93 for 318 mg, 425 mg, and 531 mg, respectively, versus -12.17 for placebo3
Placebo patients were switched over to active drug in the open-label safety extension phase3
PANSS score change from open-label safety extension baseline to end of study was -7.2 points4†
†LS mean differences versus placebo: -9.75, -11.27, and -9.76 for 318 mg, 425 mg, and 531 mg, respectively (P<.0001). 3
In an 8-week, randomized, double-blind, placebo-controlled study, WELTRUZA met the primary endpoint of change from baseline in PANSS total score at week 8 versus placebo1
The least squares (LS) mean changes from baseline to week 8 with WELTRUZA were -21.91, -23.44, and -21.93 for 318 mg, 425 mg, and 531 mg, respectively, versus -12.17 for placebo3
Placebo patients were switched over to active drug in the open-label safety extension phase3
PANSS score change from open-label safety extension baseline to end of study was -7.2 points4†
†LS mean differences versus placebo: -9.75, -11.27, and -9.76 for 318 mg, 425 mg, and 531 mg, respectively (P<.0001). 3
up next
Efficacy: secondary endpoints
See how patients treated with WELTRUZA experienced improvements in illness severity and personal and social functioning.
SEE THE DATAReferences: 1. Correll CU, Shulman K, Bar-Nur T, et al. Monthly olanzapine extended-release injectable suspension (TV-44749) for subcutaneous use leads to early, consistent symptom improvements through week 8 in adults with acute exacerbation of schizophrenia: phase 3 SOLARIS trial. Presented at: Schizophrenia International Research Society (SIRS) 2025 Annual Congress; March 29-April 2, 2025; Chicago, IL. 2. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. 3. WELTRUZA™ (olanzapine) extended-release injectable suspension Current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 4. Data on file. Clinical Study Report. November 2025. Parsippany, NJ: Teva Neuroscience, Inc.
